ANTIBODY BASED METHODS FOR 2,3,7,8-TCDD ANALYSIS

描述：（改编自申请人摘要） 二苯并二恶英和二苯并呋喃（PCDD/Fs）的含量显著增加 环境污染物 环境综合评价 影响是困难的，因为PCDD/Fs是210种可能的 氯化异构体。 此外，2，3，7，8-取代的 有毒同系物PCDD/Fs目前需要特异性、灵敏度和 高分辨率GC/MS的费用。基于抗体的分析方法 已经证明了高通量筛选和定量分析的实用性。 环境样品分析。 然而，以前的多氯二苯并对二恶英/多氯二苯并呋喃免疫测定法 发展方案并不特别成功。 有一个 对敏感的多氯二苯并对二恶英和多氯二苯并呋喃的明确的科学、商业和经济需要 毒性同源物特异性免疫测定。 该项目的目标是 开发基于实验室的免疫分析方法，可用于 大幅度降低多氯二苯并对二恶英/多氯二苯并呋喃有毒同系物分析的总费用。 第一阶段的目标是证明他们可以开发出特定的， 敏感的2，3，7，8-TetraCDD定向抗体。 第一阶段证明了这一点 目标是开发毒性当量（TEQ）指导的多克隆 基于血清的测定和灵敏的2，3，7，8-TetraCDD特异性单克隆抗体 基于抗体的测定。 第二阶段研究将制定一整套 所需的多氯二苯并对二恶英/多氯二苯并呋喃同系物特定单克隆抗体和竞争者，证明具有商业价值 通过市场引入特异性免疫测定的可行性 产品，并启动免疫亲和试剂的开发， 毫微微克灵敏测定。 拟议商业应用：不可用

DESCRIPTION: (Adapted from the applicant's abstract) Polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/Fs) are significant environmental pollutants. Comprehensive assessment of their environmental impact is difficult because the PCDD/Fs are a mixture of 210 possible chlorinated isomers. Moreover, the analysis of the 2,3,7,8-substituted toxic congener PCDD/Fs currently requires the specificity, sensitivity and expense of high resolution GC/MS. Antibody based analytical methods have demonstrated utility for both high throughput screening and quantitative analysis of environmental samples. However, previous PCDD/F immunoassay development programs have not been particularly successful. There is a clear scientific, commercial and economic need for a sensitive PCDD/F toxic congener specific immunoassays. The goal of this project is to develop laboratory based immunoanalytical methods that can be used to substantially reduce the overall cost of PCDD/F toxic congener analysis. The goal of Phase I was to prove that they could develop specific and sensitive 2,3,7,8-TetraCDD directed antibodies. Phase I demonstrated this goal with the development of a Toxic Equivalents (TEQ) directed polyclonal serum based assay and a sensitive, 2,3,7,8-TetraCDD specific monoclonal antibody based assay. The Phase II studies will develop the full set of required PCDD/F congener specific MAbs and competitors, prove commercial feasibility through the market introduction of specific immunoassay products and initiate the development of immunoaffinity reagents and femtogram sensitive assays. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE